Futura Medical PLC Final Dosing of Last Patient in MED2005 Ph3 study (4430Q)
21 Octubre 2019 - 01:00AM
UK Regulatory
TIDMFUM
RNS Number : 4430Q
Futura Medical PLC
21 October 2019
Final Dosing of Last Patient in MED2005 Phase 3 study
First European Phase 3 study "FM57" on track to deliver headline
data by the end of 2019
Patient recruitment complete for open label extension study
21 October 2019
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, is pleased to announce
that all patients have now completed dosing in the first European
Phase 3 study, "FM57", of MED2005. Futura remains on track to
deliver headline data by the end of 2019. In addition, patient
recruitment has recently been completed for the required 12 month
open-label extension study ("OLE").
Final FM57 dosing complete
FM57 is a pivotal 1,000 patient study that includes
approximately 60 centres across Central and Eastern Europe. This
Phase 3 study is a dose ranging, randomised, double blind, placebo
controlled, home use, parallel group clinical trial and evaluates
the efficacy and safety of 0.2%, 0.4% and 0.6% GTN doses of MED2005
in mild, moderate and severe erectile dysfunction ("ED")
patients.
Open Label Extension study
A 12-month open-label extension study to assess long-term safety
and tolerability of a drug is a standard regulatory requirement for
drugs intended for long-term treatment of non-life-threatening
conditions, such as ED. In line with advice received from
regulatory authorities, Futura has designed an OLE in which
subjects recruited from primarily high patient volume countries are
invited to enter into the OLE on the 0.6% dose a few days after
completing the double-blind phase and follow up visit of FM57. In
OLE studies, generally 300 to 600 patients are evaluated for 6
months and at least 100 of those patients for 12 months; defined by
the International Conference on Harmonisation (ICH) guideline E1.
Therefore, to meet this requirement, Futura are pleased to announce
that 450 subjects from the double-blind phase of FM57 have agreed
to enter the OLE study. As previously reported on 11 September 2019
interest in patients electing to enter the OLE remained high having
completed the double-blind phase of FM57.
James Barder, Chief Executive Officer, Futura Medical said: "We
are extremely pleased to have achieved this important milestone and
look forward to the Phase 3 data read out, which is on track to
deliver headline efficacy and safety data in December this year, a
key value inflection point for the Company.
"It is estimated that one in six men will experience some form
of ED in their lives. We believe MED2005 will offer new hope to ED
suffers, in an area that has seen little innovation for nearly two
decades and has the potential to be a first line treatment option
for ED."
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as
"FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study of
MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment
of erectile dysfunction with an open label extension. FM57 is
progressing on track, with headline data expected by the end of
2019.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESZMMMGKRKGLZM
(END) Dow Jones Newswires
October 21, 2019 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024